Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis
Purpose: We performed a cost-effectiveness analysis using the PHI (Prostate Health Index),
4Kscore®, SelectMDx™ and the EPI (ExoDx™ Prostate [IntelliScore]) in men with elevated …
4Kscore®, SelectMDx™ and the EPI (ExoDx™ Prostate [IntelliScore]) in men with elevated …
Whom to biopsy: prediagnostic risk stratification with biomarkers, nomograms, and risk calculators
Historically, prostate biopsy was performed because of a prostate-specific antigen (PSA)
level exceeding a specific threshold or suspicious findings on digital rectal examination …
level exceeding a specific threshold or suspicious findings on digital rectal examination …
Cost‐effectiveness of a new urinary biomarker‐based risk score compared to standard of care in prostate cancer diagnostics–a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks… - BJU …, 2017 - Wiley Online Library
Objective To assess the cost‐effectiveness of a new urinary biomarker‐based risk score
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
Biomarkers for prostate biopsy and risk stratification of patients with newly diagnosed prostate cancer
S Loeb - Urology practice, 2017 - Elsevier
Introduction Many new markers are now available as an aid for decisions about prostate
biopsy for men without prostate cancer and/or to improve risk stratification for men with …
biopsy for men without prostate cancer and/or to improve risk stratification for men with …
Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy
Purpose: We developed and validated a Prostate Health Index (Beckman Coulter, Brea,
California) based nomogram to predict prostate cancer at extended prostate biopsy …
California) based nomogram to predict prostate cancer at extended prostate biopsy …
Cost-effectiveness of urinary biomarker panel in prostate cancer risk assessment
TM Govers, L Caba, MJ Resnick - The Journal of urology, 2018 - Elsevier
Purpose SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with
traditional risk factors to individualize risk prediction for clinically significant prostate cancer …
traditional risk factors to individualize risk prediction for clinically significant prostate cancer …
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression‐based model, the prostate cancer risk calculator, and prostate‐specific antigen …
DJ Hernandez, M Han, EB Humphreys… - BJU …, 2009 - Wiley Online Library
OBJECTIVES To develop a logistic regression‐based model to predict prostate cancer
biopsy at, and compare its performance to the risk calculator developed by the Prostate …
biopsy at, and compare its performance to the risk calculator developed by the Prostate …
Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting
CR Porter, EJ Gamito, ED Crawford, G Bartsch… - Urology, 2005 - Elsevier
OBJECTIVES: To develop a model capable of predicting prostate biopsy outcomes in a
large screening population, with independent validation in the referral setting. METHODS …
large screening population, with independent validation in the referral setting. METHODS …
[HTML][HTML] Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate cancer and …, 2018 - nature.com
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
Head‐to‐head comparison of two online nomograms for prostate biopsy outcome prediction
M Oliveira, V Marques, AP Carvalho… - BJU international, 2011 - Wiley Online Library
Study Type–Diagnosis (exploratory cohort) Level of Evidence 2b What's known on the
subject? and What does the study add? In recent years, several nomograms were …
subject? and What does the study add? In recent years, several nomograms were …